Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can tweaking dialysis sodium flush out hidden salt and protect blood vessels?

NCT ID NCT06327750

Knowledge-focused Sponsor: Amsterdam UMC, location VUmc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This trial tests five different dialysis approaches in people with end-stage kidney disease to see how each affects salt stored in tissues and the health of small blood vessels. Participants receive each method in random order over four weeks. Researchers use MRI scans and skin perfusion imaging to measure changes. The goal is to understand which dialysis settings might better remove sequestered salt and improve microcirculation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Different dialysis modes and dialysate sodium concentrations
What this could lead to
If it works, this could point toward dialysis settings that better remove stored salt and improve blood vessel function, potentially reducing heart risks in kidney patients.
What could go wrong
This is a small, early cross-over study with 23 participants, so results may not apply to all patients. The effects on long-term health are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 23 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Treatment with HD or HDF 3 x per week during at least 4 hours for at least 3 months * Blood flow rate feasiblity of ≥350 ml/min * Residual diuresis \<200 ml/day * Plasma Na before dialysis 137-145 mmol/L at baseline * spKt/Vurea ≥ 1.2 * Ability to understand study procedures and willingness to provide informed consent Exclusion Criteria: * Severe incompliance to dialysis procedure and accompanying prescriptions, especially frequency and duration of dialysis treatment * Life expectancy \< 3 months due to non-renal disease * Expected transplantation within 6 months * Access recirculation \> 10% * Participation in another clinical intervention trial * Metal implants (e.g. implantable cardioverter defibrillators) * Severe obesity (MRI Ø 60 cm ≈ abdominal circumference ≤ 188 cm) * Claustrophobia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End stage renal disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End stage renal disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dianet Amsterdam

    RECRUITING

    Amsterdam, North Holland, 1105 AZ, Netherlands

  • Niercentrum aan de Amstel (Elyseklinieken)

    RECRUITING

    Amstelveen, North Holland, 1186AM, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.